PRiMeD

PRiMeD

SIF88 PRiMeD

Project Manager: David Wilkes with Boris Kovatchev, School of Medicine

The Virginia PriMeD Project: Precision Individualized Medicine for Diabetes: The purpose of this project is to detect, control (includes artificial pancreas), and cure type 1 diabetes. 

BoV Approved: December 2016

Project Dates: 2/9/2017 – 2/28/2022

Funding Awarded: $16,992,531

Executive Summary

Detection -> Control ->Cure. In the world of type 1 diabetes (T1D), these words represent a process that begins with genetic screening and early detection, employs the artificial pancreas to optimally control the disease, and aspires to a cure that will defy autoimmunity and regenerate beta cells. Interdisciplinary teams led by Drs. Stephen Rich, Boris Kovatchev and Andy Basu, and Larry Lum, respectively, are interacting through this award to create a research and clinical environment that is unique, and which positions the University as a World leader in the T1D field. The strategic goals  of this project are: 

  1. Detection: Establish a statewide network to provide genetic screening for T1D;
  2. Control: Create new Diabetes Data Science to unleash the power of analytics and offer: a. Optimal diabetes control based on UVA’s advanced artificial pancreas technology; b. An interdisciplinary Graduate Program to students with science/engineering background; and c. A State-of-the-art Clinical Center to bring technology to patients;
  3. Cure: Chart the road by investing in emerging immunotherapies and islet replacement treatments.

 

Current Status: Active

Progress

Three full PAC reviews and one administrative review have been conducted, each with positive final results. The project team has created the administrative infrastructure necessary to pursue multiple industry collaborations and Center grants, necessary to sustain the Center beyond the life of the SIF award. They have opened a diabetes technology clinic, translating research to the patient population. They have developed educational resources and are implementing programs with the CME office to educate UVA and other community providers on the use of diabetes technology. They have created a statewide database to identify and track children at risk of developing Type 1 Diabetes (T1D). And, finally, they are making progress with the development of novel T regulatory cells toward the treatment of T1D.